Table 3.
ctDNA | CTC | Extracellular Vesicles | |
---|---|---|---|
Advantages | |||
Detection of tumor heterogeneity | √ | √ | √ |
Offers RNA- and DNA-based measurements | √ | √ | |
Use of standardized methodology exemplified by CE-IVD platform for enumeration and capturing and ctDNA mutation and methylation assays | √ | √ | |
Can monitor disease progression and relapse | √ | √ | |
Disadvantages | |||
Present in low numbers—large amount of sample required | √ | √ | |
Patient-derived material is specific to a disease stage exemplified by CTC in metastatic disease | √ | ||
Extensive analytic and clinical validity required | √ | √ |